21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 01.11.2026 Expectation: 100 pips
Invest in ETHUSD with $2,790 target
Today at 06:30 AM 12
Period: 30.11.2026 Expectation: 5000 pips
Go long on USDJPY with 162.00 target as dollar strengthens
Today at 04:22 AM 11
Period: 07.10.2026 Expectation: 900 pips
Buy NVIDIA up to $236
Yesterday at 11:07 AM 20
Period: 01.11.2026 Expectation: 3500 pips
Invest in USDCAD with 1.45500 in sight
Yesterday at 09:54 AM 17
Period: 29.10.2026 Expectation: 3100 pips
BTCUSD sell-off targets $80,000
29 September 2026 29
Period: 31.10.2026 Expectation: 600 pips
Selling EURUSD on Fed’s harsh rhetoric
29 September 2026 22
Go to forecasts